Summary Thefo lP l gene of Mycobacterium leprae, which encodes dihydropteroate synthase (DHPS), was studied for the presence of mutations associated with resistance to dapsone (DDS). When the fo lP l of several DDS-resistant clinical isolates of M. leprae were sequenced, two missense mutations were identified. One mutation occurred at codon 53, substituting isoleucine for threonine in DHPS-l, and a second mutation occurred in codon 55, substituting arginine for proline. DNA sequencing of strains of M. leprae resistant to 0·01 g% DDS in the mouse diet revealed that 13 of 14 strains contained either the 53 or 55 fo lP l mutation. None of the susceptible strains and only one of five strains resistant to 0·00 1 g% DDS revealed a mutation infolP l, suggesting that only high-level DDS resistance is associated with the mutations identified in folP I. Development and application of simple molecular tests to assess drug-related mutations in M. leprae could establish current levels of drug resistance in leprosy as a reference point for future monitoring of drug resistance at the global level.
In this era of declining leprosy prevalence, control measures could be in jeopardy. Potential threats that could undermine current gains toward the global elimination of leprosy are both operational and technical. Operationally, maintenance of dedicated personnel and expertise in diagnosis and treatment of leprosy may become more difficult as vertical programs become integrated into general health systems. Technical issues remaining unsolved or poorly understood in the struggle to control leprosy globally include the lack of a highly effective vaccine, the rise of immunodeficiency diseases in populations harbouring leprosy, and the potential for emergence of drug-resistant strains of Mycobacterium Zeprae.
Resistance to dapsone (DDS) was the first indication that new drug therapies were needed. l , 2 The multidrug therapy (MDT) regimen recommended by the World Health Organization (WHO) for the treatment of multibacillary leprosy was designed to prevent emergence of drug resistance, while providing shortened and affordable treatment schedules required in developing countries. Now, despite our having implemented MDT for more than 15 years in various parts of the world, we do not have reliable measurements of drug resistance in the remaining pool of M. Zeprae.
Recent advances in the elucidation of molecular events responsible for drug resistance in mycobacteria have allowed the development of new tools for screening for drug resistance, 3 -5 and application of these tools has revealed the existence of both monoresistant 6 and multidrug-resistant 7 strains of M. leprae. Recently, point mutations in the putative M. leprae gene for dihydropteroate synthase (jo IP) have been identified in DDS-resistant strains of M. leprae, 8 . 9 and definitive evidence linking these mutations with DDS resistance and proof of enzymatic activity of the putative dihydropteroate synthase (DHPS) of M. leprae have been obtained. 10 A more complete understanding of the mechanism of action of DDS and the modes of resistance available to M. leprae should facilitate the development of new tools for monitoring DDS resistance, and initiate investigations into new strategies to circumvent this phenomenon. In this study we extend our earlier findings with respect to mutations associated with DDS resistance, and discuss the need for developing and implementing new molecular tests for screening M. leprae for drug resistance.
Materials and methods

BACTERIAL STRAINS
DDS-resistant and susceptible strains of M. leprae were obtained originally from leprosy patients from: the Anandaban Leprosy Hospital, Kathmandu, Nepal; Leprosy Research Center, National Institute of Infectious Disease, Tokyo, Japan; Schieffelin Leprosy Research and Training Center, Karigiri, India; and G. W. Long Hansen's Disease Center, Carville, LA (see Table 1 ). Resistance to DDS was determined in the mouse footpad system by Shepard's kinetic method, 1 1 and all dapsone-resistant strains were propagated thereafter in the footpads of BALB!c mice fed mouse chow containing appropriate concentrations of DDS ad libitum. DDS-resistant strains grew in footpads of mice administered DDS in a concentration of either 0·001 or 0·01 g per 100 g mouse chow. These concentrations represent lO-fold and 100-fold, respectively, the minimal effective dose (MED) for susceptible strains of M. leprae. Thai-53, a DDS-susceptible strain of M. leprae, was the kind gift of Dr M. Matsuoka, Leprosy Research Center, Tokyo, Japan.
Bacterial DNA was harvested from ethanol-fixed tissues containing M. leprae following rehydration for 60 min in 10mM Tris, 1 mM EDTA buffer, pH 7·4 (TE). The rehydrated tissue was minced with scissors to a gelatinous consistency, resuspended in 0·3 ml TE buffer, frozen in liquid N 2 , and thawed at 95°C, after which the freezing/thawing treatment was repeated two more times. The tissue was then digested for 18 h at 60°C with proteinase K (2'5 mg per ml) in 100 mM Tris, 150mM NaCI, 10mM EDTA, pH 7·4 digestion buffer. Proteinase K was heat-inactivated at 95°C for 10 min, and DNA was extracted by phenoUchloroformlisoamyl alcohol as described previously. 1 2 The precipitated DNA was resuspended in 30 J.tl TE buffer.
DNA SEQUENCING OF DDS RESISTANT AND SUSCEPTIBLE STRAINS OF M. LEPRA E
The entire fo lP l was amplified by PCR from DNA preparations of DDS-susceptible and resistant strains of M. leprae with the aid of fo1P1-1 and folP l-2 primer sets. I O PCR fragments were purified, and the DNA sequence offolPl was obtained using foIP1-1, foIP l-2, folP l-9 and folP l-20 primers. 10 The sequence of fo lP l from each strain was compared to that of a DDS-susceptible strain of M. leprae found in the Sanger Centre database, Cambridge, England (www.sanger.ac.uk). C Designation of the mutation in fo /P l associated with dapsone resistance.
Results and discussion
The dihydropteroate synthase (DHPS) of M. leprae is encoded by fo LP1, which is located in an operon encoding three other genes (fo IE, fo lB and fo lK) putatively involved in folate biosynthesis (see Figure 1) . The amino acid sequence of the DHPS of M. leprae, deduced from the DNA-sequence of fo lP l, identified a protein of approximately 31 kDa molecular weight, with two signature regions (PS00792 and PS00793) associated with fo lP enzymes from diverse bacterial species, including Bacillus subtilis and Neisseria meningitides. 1O The second signature motif is the region in which mutations have been shown to induce resistance to sulphonamide and sulphone compounds in bacteria, including M. leprae. IO , 13 , 14 Mutations at amino-acid residues 53 and 55 in this region of M. leprae fo lP 1 have been shown to be associated with DDS resistance, and to confer increased resistance to DDS by recombinant Escherichia coli that express only mutant DHPS obtained from M. leprae. 1O Further analysis of DDS-resistant strains of M. leprae has confirmed our earlier findings, showing mutations in codons representing amino acids 53 (threonine) and 55 (proline) of the DHPS of M. leprae, as shown in Table 1 . Missense mutations found in codon 53, resulting in a substitution of alanine, arginine or isoleucine for threonine, were found only III DDS-resistant strains that multiplied in mice administered DDS in 100-fold the MED. Signature region 2 encompasses amino acids 53 and 55, in which mutations were found associated with DDS resistance. Genes in the operon are: folE, which encodes GTP cyclohydrolase;j oLP, which encodes hydydropteroate synthase; fo LB, which encodes dihydroneopterin aldolase; and fo lK, which encodes dihydropteridine pyrophosphokinase.
Missense mutations at codon 55, resulting in substitutions of either arginine or leucine for proline, were most often identified in strains that grew at 100-fold the MED for DDS. Only one strain of DDS-resistant M. leprae, which multiplied in mice administered DDS in lO-fold the MED, contained a missense mutation at codon 55. All other strains resistant at lO-fold the MED showed the fully susceptible genotype. Although analysis of these strains is as yet incomplete, it is interesting to speculate why most of these phenotypes do not have mutations infolP I. In the pre-MDT era, clinical experience showed that patients infected with strains of M. leprae resistant to low and moderate levels of DDS responded to DDS monotherapy. It may be that low and moderate levels of DDS resistance are artefacts of the mouse footpad assay, and lack clinical significance. Alternatively, these low and moderately resistant strains may represent 'mutants' that foster the development of high-level resistance upon selection of the fo lP I mutations identified above. Finally, the significance of these strains in terms of 'real' DDS resistance remains to be elucidated.
That the resistant strains analysed in this study originated from at least three different parts of the world suggests that DDS resistance exists in many areas of the world. The most recent surveys for DDS resistance were done by de Ia Cruz et al. 15 and Budin et al. 1 6 In both instances, treatment of the patient population with MDT had been in place for 10-12 years, despite which significant levels of high-level DDS resistance was observed. In Cebu, the Philippines, the frequency of DDS resistance at all three levels has been increasing over the last 20 years.
In addition to DDS-resistant strains of M. leprae, monoresistant strains resistant to rifampicin have been identified. 1 7 In most cases, these were the result of drug-trials in which rifampicin was administered as monotherapy. A recent report has also identified a multi drug resistant strain of M. leprae resistant to DDS, rifampin, and ofioxacin. 7 These strains were selected under pressure from drugs now in common use for treating leprosy. As drug regimens continue to be shortened in an attempt to find the minimal duration of chemotherapy that is capable both of effecting cure and preventing the selection of drug-resistant mutants, we must remain alert to the possibility of emerging drug resistance in leprosy. New molecular tests based on mutations associated with drug resistance are needed to permit simplified monitoring in many regions of the world. This is especially important as the number of laboratories carrying out the mouse footpad technique is diminishing around the world, and an atmosphere of complacency surrounds leprosy control programmes as prevalence falls.
